Trials / Active Not Recruiting
Active Not RecruitingNCT03455452
Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer
A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) With or Without Ipilimumab (BMS-734016) in Patients With Advanced Renal Cell Carcinoma in Real Life Setting
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a French, nationwide, prospective, observational, multi-center study in participants diagnosed with advanced renal cell carcinoma, who start a new systemic therapy with nivolumab with or without ipilimumab for the first time and within the market authorization approval.
Conditions
- Renal Cell Carcinoma
- Renal Cell Cancer
- Adenocarcinoma Of Kidney
- Adenocarcinoma, Renal Cell
- Kidney Cancer
- Cancer of the Kidney
Timeline
- Start date
- 2018-01-21
- Primary completion
- 2025-11-30
- Completion
- 2025-11-30
- First posted
- 2018-03-06
- Last updated
- 2025-06-25
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03455452. Inclusion in this directory is not an endorsement.